Equities research analysts expect ArQule, Inc. (NASDAQ:ARQL) to announce earnings of ($0.10) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for ArQule’s earnings. ArQule reported earnings per share of ($0.08) during the same quarter last year, which indicates a negative year-over-year growth rate of 25%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, May 3rd.

According to Zacks, analysts expect that ArQule will report full year earnings of ($0.44) per share for the current year. For the next financial year, analysts anticipate that the business will report earnings of ($0.42) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover ArQule.

ArQule (NASDAQ:ARQL) last released its quarterly earnings data on Tuesday, March 7th. The biotechnology company reported ($0.10) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.10). The firm earned $1.19 million during the quarter, compared to analyst estimates of $1.20 million. ArQule had a negative return on equity of 55.62% and a negative net margin of 296.69%. During the same quarter in the prior year, the firm posted ($0.05) earnings per share.

Separately, Zacks Investment Research cut ArQule from a “hold” rating to a “sell” rating in a research report on Thursday, February 23rd.

ArQule (NASDAQ:ARQL) traded down 8.57% during mid-day trading on Tuesday, hitting $0.96. The stock had a trading volume of 147,752 shares. The stock’s market cap is $68.29 million. The stock’s 50-day moving average price is $1.14 and its 200-day moving average price is $1.34. ArQule has a 12 month low of $0.92 and a 12 month high of $2.17.

An institutional investor recently raised its position in ArQule stock. Renaissance Technologies LLC increased its position in shares of ArQule, Inc. (NASDAQ:ARQL) by 1.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,017,600 shares of the biotechnology company’s stock after buying an additional 26,900 shares during the period. Renaissance Technologies LLC owned about 2.84% of ArQule worth $2,542,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 58.99% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “-$0.10 EPS Expected for ArQule, Inc. (ARQL) This Quarter” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/04/18/0-10-eps-expected-for-arqule-inc-arql-this-quarter.html.

ArQule Company Profile

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

5 Day Chart for NASDAQ:ARQL

Get a free copy of the Zacks research report on ArQule (ARQL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with MarketBeat.com's FREE daily email newsletter.